VERA

Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics, Inc. (VERA) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Value (D+). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
D+
Factor Score 1.7 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -7.2
EV / EBITDA -4.0
Rev Growth YoY N/A
Gross Margin 67.9%
Price Return 3M -11.2%
Price Return 12M -9.6%
Catalyst Signal 0.00
Market Cap $2.0B
TTM Revenue $10.3M
Price / Sales 197.7
ROE -113.5%

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 D+ (1.7) B- (3.1) C+ (2.8) C (2.4) C+ (2.6) C+ (2.5)
2026-11-08 D+ (1.7) B- (3.1) C+ (2.7) C+ (2.7) C+ (2.6) C+ (2.6)
2026-11-01 C+ (2.5) B- (2.9) C- (2.1) C+ (2.7) C+ (2.7) C+ (2.6)
2026-10-25 C+ (2.5) C+ (2.8) C- (2.0) C (2.2) C+ (2.6) C (2.5)
2026-10-18 C+ (2.5) C+ (2.8) C- (2.0) C- (2.1) C+ (2.6) C (2.4)
Page 1 of 3